Xeris Biopharma Holdings, Inc. $XERS Shares Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. increased its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 108.3% in the second quarter, Holdings Channel.com reports. The firm owned 1,227,959 shares of the company’s stock after purchasing an additional 638,488 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Xeris Biopharma were worth $5,735,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Los Angeles Capital Management LLC acquired a new stake in Xeris Biopharma in the 2nd quarter worth about $95,000. Savvy Advisors Inc. acquired a new position in Xeris Biopharma during the second quarter worth approximately $189,000. Y Intercept Hong Kong Ltd boosted its holdings in shares of Xeris Biopharma by 655.2% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 336,214 shares of the company’s stock valued at $1,570,000 after purchasing an additional 291,696 shares during the last quarter. Janney Montgomery Scott LLC purchased a new position in shares of Xeris Biopharma in the 2nd quarter worth $118,000. Finally, Rhumbline Advisers boosted its holdings in Xeris Biopharma by 6.3% in the first quarter. Rhumbline Advisers now owns 192,281 shares of the company’s stock valued at $1,056,000 after acquiring an additional 11,317 shares during the last quarter. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Marla Persky sold 15,500 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $7.72, for a total value of $119,660.00. Following the completion of the transaction, the director owned 142,000 shares in the company, valued at approximately $1,096,240. This trade represents a 9.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey W. Sherman sold 42,232 shares of the business’s stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $7.92, for a total value of $334,477.44. Following the completion of the sale, the director owned 219,188 shares of the company’s stock, valued at $1,735,968.96. This trade represents a 16.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 74,399 shares of company stock worth $577,473. Corporate insiders own 6.47% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on XERS. Leerink Partners boosted their target price on Xeris Biopharma from $7.00 to $9.00 and gave the stock an “outperform” rating in a report on Tuesday, August 19th. Piper Sandler lifted their price target on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Zacks Research cut shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 30th. Oppenheimer reiterated an “outperform” rating and set a $18.00 target price on shares of Xeris Biopharma in a report on Friday, November 7th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Xeris Biopharma in a research note on Friday, November 7th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $9.58.

Xeris Biopharma Trading Down 4.3%

Shares of NASDAQ:XERS opened at $7.26 on Friday. The firm has a market cap of $1.20 billion, a PE ratio of -72.59 and a beta of 0.21. The company has a fifty day simple moving average of $8.36 and a 200 day simple moving average of $6.46. Xeris Biopharma Holdings, Inc. has a 12-month low of $2.82 and a 12-month high of $10.08.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.